Regulation of Intrinsic Functions of PD-L1 by Post-Translational Modification in Tumors.
Regulation of Intrinsic Functions of PD-L1 by Post-Translational Modification in Tumors.
复制标题
DOI：
10.3389/fonc.2022.825284
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
Miki Y
中科院分区：
文献类型：
--
作者：
Nihira NT;Miki Y
肿瘤细胞被免疫系统清除，包括T淋巴细胞和自然杀伤细胞;然而，许多类型的肿瘤细胞通过免疫检查点分子抑制T细胞活化和功能来获得免疫耐受。靶向免疫检查点分子（如程序性死亡受体1（PD-1）/程序性死亡配体1（PD-L1）和细胞毒性T淋巴细胞相关蛋白4（CTLA-4））的免疫疗法已显示出多种癌症治疗的成功结果，但一些患者显示缺乏持久的反应。因此，发现操纵免疫检查点分子的表达或功能的化合物或药物有望克服免疫检查点抑制剂的耐药性。抑制性免疫检查点分子的功能通常通过肿瘤中的转录和翻译后水平失调。在这里，这篇综述的重点是内在PD-L1功能和PD-L1转录调节因子的翻译后修饰。
Tumor cells are eliminated by the immune system, including T lymphocytes and natural killer cells; however, many types of tumor cells acquire the immune tolerance by inhibiting T-cell activation and functions via immune checkpoint molecules. Immunotherapy targeting immune checkpoint molecules such as Programmed death receptor 1 (PD-1)/Programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) have shown successful outcomes for multiple cancer treatments, however some patients show the lack of durable responses. Thus, discovering the chemical compounds or drugs manipulating the expression or function of immune checkpoint molecules are anticipated to overcome the drug resistance of immune checkpoint inhibitors. Function of inhibitory immune checkpoint molecules is often dysregulated by the transcriptional and post-translational levels in tumors. Here, this review focuses on the post-translational modification of intrinsic PD-L1 functions and regulators for PD-L1 transcription.
登录
查看更多内容
DOI：
10.1084/jem.20100619
发表时间：
2011-03-14
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Wang L;Rubinstein R;Lines JL;Wasiuk A;Ahonen C;Guo Y;Lu LF;Gondek D;Wang Y;Fava RA;Fiser A;Almo S;Noelle RJ
通讯作者：
Noelle RJ
DOI：
10.1126/science.aac9935
发表时间：
2016-04-08
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Casey SC;Tong L;Li Y;Do R;Walz S;Fitzgerald KN;Gouw AM;Baylot V;Gütgemann I;Eilers M;Felsher DW
通讯作者：
Felsher DW
影响因子：
16.6
作者：
Sato H;Niimi A;Yasuhara T;Permata TBM;Hagiwara Y;Isono M;Nuryadi E;Sekine R;Oike T;Kakoti S;Yoshimoto Y;Held KD;Suzuki Y;Kono K;Miyagawa K;Nakano T;Shibata A
通讯作者：
Shibata A
DOI：
10.1158/1078-0432.ccr-15-0244
发表时间：
2015-09-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Taube JM;Young GD;McMiller TL;Chen S;Salas JT;Pritchard TS;Xu H;Meeker AK;Fan J;Cheadle C;Berger AE;Pardoll DM;Topalian SL
通讯作者：
Topalian SL
DOI：
10.1158/1078-0432.ccr-16-3215
发表时间：
2017-07-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Jiao S;Xia W;Yamaguchi H;Wei Y;Chen MK;Hsu JM;Hsu JL;Yu WH;Du Y;Lee HH;Li CW;Chou CK;Lim SO;Chang SS;Litton J;Arun B;Hortobagyi GN;Hung MC
通讯作者：
Hung MC